Hospital
Slidell Memorial Hospital
Slidell Memorial Hospital was paid $11.85M by Medicaid between Jan 2018 and Dec 2024, across 134 billing codes. Its largest line is 99284, emergency room visit (serious) — 23% of everything it billed.
33Billing provider infoSLIDELL MEMORIAL HOSPITAL
SLIDELL, LA 70458
SLIDELL, LA 70458
33aNPI1578568481assigned 06/16/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$11.85M
24GClaims433,447
24DCodes billed134
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Louisiana
Rank by total paid#33 of 96
Median peer was paid$5.17M
This provider vs. median2.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 39,044 | $1.28M | |
| 2019 | 42,734 | $1.22M | |
| 2020 | 30,863 | $720K | |
| 2021 | 68,502 | $1.80M | |
| 2022 | 86,167 | $2.43M | |
| 2023 | 103,715 | $2.59M | |
| 2024incomplete | 62,422 | $1.82M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 23% | 34,246 | 31,120 | $2.78M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 21% | 24,987 | 21,746 | $2.47M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 11% | 21,666 | 19,959 | $1.32M |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 5.0% | 15,942 | 14,271 | $589K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 4.4% | 7,400 | 6,512 | $522K |
| 80053 | Comprehensive metabolic panel | 3.0% | 50,348 | 41,221 | $359K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 2.6% | 5,851 | 5,388 | $302K |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.3% | 5,612 | 3,988 | $270K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.2% | 15,415 | 13,236 | $263K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.2% | 51,100 | 41,593 | $263K |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 2.2% | 5,868 | 5,218 | $255K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.9% | 11,222 | 8,695 | $224K |
122 more codes
| 71045 | Radiologic examination, chest; single view | 1.3% | 8,278 | $160K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.3% | 1,438 | $153K |
| G0378 | Hospital observation service, per hour | 1.2% | 1,475 | $141K |
| 81025 | 1.2% | 21,989 | $137K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.1% | 2,841 | $134K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.1% | 470 | $133K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.0% | 6,909 | $124K |
| 71046 | Radiologic examination, chest; 2 views | 1.0% | 4,274 | $119K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.0% | 3,083 | $119K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,140 | $112K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,892 | $83K |
| 36415 | Collection of venous blood by venipuncture | <1% | 34,226 | $72K |
| 84484 | <1% | 9,555 | $69K | |
| 83880 | <1% | 3,345 | $67K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 2,312 | $63K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 4,208 | $49K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 600 | $36K |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 62 | $31K |
| 81001 | <1% | 12,928 | $28K | |
| 83690 | <1% | 5,758 | $27K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 1,104 | $20K |
| 83735 | <1% | 5,449 | $20K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 260 | $15K |
| G0330 | Facility services for dental rehabilitation procedure(s) performed on a patient who requires monitored anesthesia (e.g., general, intravenous sedation (monitored anesthesia care) and use of an operating room | <1% | 24 | $13K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 650 | $13K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 700 | $13K |
| 59025 | Fetal non-stress test | <1% | 315 | $13K |
| 80061 | Lipid panel | <1% | 1,095 | $12K |
| 81003 | <1% | 8,163 | $12K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 391 | $12K |
| 87400 | <1% | 821 | $11K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 255 | $10K |
| 73630 | <1% | 210 | $8K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 389 | $8K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 67 | $7K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 626 | $7K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 125 | $7K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,603 | $7K |
| 96367 | <1% | 473 | $7K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 306 | $7K |
| 80050 | General health panel | <1% | 191 | $7K |
| 82550 | <1% | 1,321 | $7K | |
| 82728 | <1% | 705 | $6K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 143 | $6K |
| 82553 | <1% | 701 | $6K | |
| 84466 | <1% | 677 | $6K | |
| 85610 | <1% | 2,136 | $5K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 546 | $5K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 790 | $5K |
| 85730 | <1% | 1,085 | $4K | |
| 31720 | <1% | 12 | $4K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 186 | $4K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 17 | $4K |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 2,058 | $4K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 28 | $4K |
| 80179 | <1% | 370 | $4K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 273 | $4K |
| 87486 | <1% | 121 | $3K | |
| 87581 | <1% | 123 | $3K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 254 | $3K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 153 | $3K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 354 | $3K |
| 83540 | <1% | 676 | $3K | |
| 86900 | <1% | 86 | $2K | |
| 86803 | <1% | 174 | $2K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,639 | $2K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 466 | $2K |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 770 | $2K |
| 84439 | <1% | 221 | $2K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 28 | $2K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 896 | $2K |
| 90686 | <1% | 382 | $2K | |
| 94760 | <1% | 152 | $2K | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 254 | $2K |
| 87081 | <1% | 250 | $1K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 225 | $1K |
| 81000 | <1% | 587 | $1K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 49 | $1K |
| 87634 | <1% | 26 | $1K | |
| 80143 | <1% | 105 | $1K | |
| 87070 | <1% | 141 | $1K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 62 | $928.58 |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 13 | $810.98 |
| 86901 | <1% | 86 | $743.39 | |
| 76830 | Ultrasound, transvaginal | <1% | 13 | $709.64 |
| 82948 | <1% | 167 | $691.55 | |
| 80329 | <1% | 32 | $659.41 | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 14 | $612.46 |
| 87430 | <1% | 54 | $612.25 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 43 | $550.12 |
| 85027 | <1% | 142 | $548.15 | |
| 94761 | <1% | 312 | $538.26 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 12 | $509.88 |
| 82150 | <1% | 97 | $477.54 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 109 | $454.57 |
| 82962 | <1% | 271 | $441.47 | |
| 96376 | <1% | 96 | $427.75 | |
| 80320 | <1% | 33 | $403.80 | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 22 | $377.65 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 530 | $234.61 |
| 83605 | <1% | 50 | $232.89 | |
| 87807 | <1% | 32 | $209.86 | |
| 84702 | <1% | 15 | $195.95 | |
| J2704 | Injection, propofol, 10 mg | <1% | 703 | $190.74 |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 13 | $179.08 |
| 84100 | <1% | 88 | $158.27 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 42 | $150.46 |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 71 | $149.59 |
| 80069 | <1% | 31 | $130.65 | |
| 87040 | <1% | 26 | $93.05 | |
| 86140 | <1% | 23 | $83.13 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 109 | $70.36 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 559 | $63.23 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 155 | $38.50 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 70 | $22.75 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 526 | $18.00 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 50 | $6.30 |
| J3490 | Unclassified drugs | 0% | 1,655 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 39 | $0.00 |
| J1597 | Injection, glycopyrrolate (glyrx-pf), 0.1 mg | 0% | 13 | $0.00 |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | 0% | 3,210 | $0.00 |
| 00170 | Anesthesia for intraoral procedures, including biopsy | 0% | 22 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBADINGER, SANDRA (CEO)
| Provider | Location | Paid |
|---|---|---|
| Slidell Memorial Hospital | Slidell, LA | $3.27M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.